When a medical device is implanted into the human body (whether temporarily or permanently) it triggers a biological response. The difference between safe integration and harmful inflammation can determine patient outcomes, regulatory approval, and product success. ISO 10993-6:2026 — Biological evaluation of medical devices – Part 6: Tests for local effects after implantation, part of the globally recognized ISO 10993 biocompatibility series, plays a critical role. This international standard defines how manufacturers must evaluate local tissue effects after implantation, assuring that devices interact safely with the body before reaching clinical use.
What Are Implanted Medical Devices?
Implanted medical devices are instruments placed inside or on the surface of the body—surgically or via medical intervention—to replace, support, or monitor biological functions. Common types include pacemakers, orthopedic implants, stents, and pumps. These devices are made of metal, ceramics, or polymers and are used for long-term or permanent support.
Importance of Addressing Tissue Response to Implanted Medical Devices
Implanted devices interact directly with surrounding tissue and poor compatibility can lead to chronic inflammation, fibrosis or encapsulation, device rejection, and/or infection risk. Therefore, addressing tissue responses to implanted medical devices is essential to assure long-term device functionality, patient safety, and successful integration within the body.
Based on industry research and regulatory data, biocompatibility issues, inadequate material characterization, and related chemical/sterilization failures remain leading causes of medical device recalls and regulatory delays. This stresses the importance of standards like ISO 10993-6:2026 for risk mitigation.
What Is ISO 10993-6:2026?
ISO 10993-6:2026 specifies requirements for implantation test methods for preclinical assessment of the local effects after implantation of medical devices or materials intended for use in medical devices.
It is applicable to the evaluation of local tissue responses from medical devices used where skin or mucosal tissue is breached. ISO 10993-6:2026 is also applicable to medical devices or materials that require implantation evaluation; such devices or materials can be solid or non-solid (such as porous materials, liquids, gels, pastes, powders, and particulates), absorbable, degradable, non- absorbable, or can be tissue-engineered medical products (TEMPs).
These implantation tests are not intended to evaluate or determine the performance of the test sample in terms of mechanical loading or functional performance. ISO 10993-6:2026 also does not provide guidance on methods and study design to satisfy requirements for systemic toxicity, carcinogenicity, teratogenicity or mutagenicity. However, the study designs can be modified to also assess other biological effects.
Changes in the 2026 Edition of ISO 10993-6
ISO 10993-6:2026 is the 4th edition of the standard focused specifically on implantation testing. The main changes in ISO 10993-6:2026 are as follows:
- Informative elements of the scope have been moved to the introduction
- New definitions for “comparative control,” “coupon,” “euthanasia,” “local effect,” “location marker,” “steady-state,” and “reference control” have been added to Clause 3, Terms and definitions
- A new paragraph on the use of smaller compositionally representative samples or coupons has been added to 4.2.2
- A new subclause 4.3 “Selection of control materials” has been added
- The discussion of assessment of lymph nodes for certain materials has been expanded
- A new Annex E, “Test methods for devices contacting peripheral nerve tissue,” and Annex G, “Microscopic evaluation of tissue responses to implanted materials,” have been added
- Tissue and pathological terminology have been updated throughout this document
- The old Annex E from ISO 10993-6:2016 has become Annex F, Examples of scoring systems used to support the evaluation of local biological effects after implantation
- Bibliographical entries have been updated
The Growing Importance of Implantation Testing
Implantable medical devices are central to modern healthcare. From orthopedic implants to cardiovascular devices, millions of patients worldwide rely on these devices each year. The global implantable medical devices market size was valued at USD 97.17 billion in 2024 and is predicted to hit around USD 176.33 billion by 2034.
This market is rising because the global surge in chronic diseases as well as the ageing population are driving demand for implantable medical solutions. As such, it is critical to assure the safety of implanted medical devices. ISO 10993-6:2026 plays a foundational role in doing so.
Where to Find ISO 10993-6:2026
By standardizing how local tissue effects are evaluated, ISO 10993-6:2026 can help manufacturers reduce risk, improve product design, and achieve regulatory approval faster. Thus, ISO 10993-6:2026 is paramount for earning trust from regulators, clinicians, and patients.
ISO 10993-6:2026 — Biological evaluation of medical devices – Part 6: Tests for local effects after implantation is available on the ANSI Webstore.